<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of hairy cell leukemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of hairy cell leukemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of hairy cell leukemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Tallman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hairy cell leukemia (HCL) is an uncommon lymphoid neoplasm characterized by the accumulation of small mature B cell lymphoid cells with abundant cytoplasm and "hairy" projections within the peripheral blood, bone marrow, and splenic red pulp. This accumulation of neoplastic cells typically results in splenomegaly; a variable reduction in the production of normal red blood cells, platelets, mature granulocytes, and monocytes; and complications of anemia, bleeding, and infection.</p><p>The treatment of HCL will be reviewed here; clinical features and diagnosis of this disorder are discussed separately. (See  <a class="medical medical_review" href="/d/html/4532.html" rel="external">"Clinical features and diagnosis of hairy cell leukemia"</a>.)</p><p class="headingAnchor" id="H3247744983"><span class="h1">PRETREATMENT EVALUATION</span><span class="headingEndMark"> — </span>The initial evaluation of patients with HCL must establish the precise diagnosis, the extent of disease, and the performance status of the patient. Particular attention should be paid in the history and physical examination to palpable enlargement of the spleen, liver, and/or lymph nodes and history of recent infections.</p><p>Our pretreatment evaluation also includes the following studies, some of which are performed as part of the diagnostic evaluation (see  <a class="medical medical_review" href="/d/html/4532.html" rel="external">"Clinical features and diagnosis of hairy cell leukemia", section on 'Evaluation'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory studies include a complete blood count with differential and evaluation of the peripheral smear, chemistries with liver and renal function and electrolytes, uric acid, and lactate dehydrogenase. Hepatitis B and C serology should be obtained, especially for patients whose planned treatment includes <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Flow cytometry of the peripheral blood to confirm the immunophenotype of the circulating mononuclear cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unilateral bone marrow biopsy is recommended for all patients; an aspirate should be attempted but is often not attainable (dry tap). This sample should be sent for pathologic review with morphologic evaluation and immunohistochemistry. All cases should be evaluated for the <em>BRAF</em> V600E mutation using a highly sensitive technique (ie, allele-specific polymerase chain reaction or next-generation sequencing). If a highly sensitive technique is not available, immunohistochemical staining for VE1 may identify this mutation on bone marrow biopsy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Imaging is not a standard part of the evaluation of patients outside of a clinical trial but is appropriate for the evaluation of suspected complications such as infection or symptoms related to organomegaly or lymphadenopathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women of childbearing age should have a serum pregnancy test if chemotherapy or radiation therapy is planned.</p><p></p><p class="headingAnchor" id="H483044512"><span class="h1">THERAPEUTIC STRATEGY</span></p><p class="headingAnchor" id="H1045642582"><span class="h2">Goals of care</span><span class="headingEndMark"> — </span>While not curative, modern therapy for HCL can alleviate symptoms, reverse cytopenias, and prolong survival to a near normal lifespan. Most patients can achieve durable remissions with long treatment-free periods followed by further therapy when symptomatic relapse occurs.</p><p class="headingAnchor" id="H2"><span class="h2">Indications for treatment</span><span class="headingEndMark"> — </span>Many patients with HCL are asymptomatic and can be observed for months or years after the diagnosis is established before requiring treatment. There is no clear advantage to early treatment; therapy is indicated only when the patient develops one or more of the following problems or symptoms [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/4532.html" rel="external">"Clinical features and diagnosis of hairy cell leukemia", section on 'Presenting symptoms or signs'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Significant cytopenias; typical peripheral blood counts that warrant treatment include an absolute neutrophil count &lt;1000/microL, hemoglobin concentration &lt;11 g/dL, or platelet count &lt;100,000/microL</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic splenomegaly (common) or symptomatic adenopathy (uncommon)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Constitutional symptoms (eg, fever, night sweats, fatigue, weight loss)</p><p></p><p>Treatment may also be appropriate for patients with less severe cytopenias that are symptomatic (eg, repeated infections, bleeding) and for those with progressive lymphocytosis [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H725721107"><span class="h2">Asymptomatic patients</span><span class="headingEndMark"> — </span>As described above, immediate treatment is indicated in patients with active disease manifest as significant cytopenias, symptomatic splenomegaly or adenopathy, or severe disease-related constitutional symptoms. Otherwise, a period of observation is recommended.</p><p>During this observation period, the frequency of visits depends on the severity and tempo of disease. Most patients can be seen in clinic every three months for the first year and then every three to six months thereafter until indications for therapy arise. At these visits we perform a history, physical examination, and a complete blood count with differential.</p><p class="headingAnchor" id="H2946334293"><span class="h2">Infections</span><span class="headingEndMark"> — </span>Historically, infection has been a major cause of death in patients with HCL [<a href="#rid1">1-4</a>]. These patients have an increased risk of infection due to a combination of disease-related immunosuppression (eg, neutropenia and/or monocytopenia) and treatment-related immunosuppression. In addition to increased rates of bacterial, viral, and fungal infections, patients with HCL appear to be at increased risk of nontuberculous mycobacterial infections [<a href="#rid5">5</a>].</p><p>The following specific issues related to infectious complications are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Purine analogs suppress immune effector cells and induce a profound neutropenia and prolonged lymphopenia. Risk of infection with purine analogs and antimicrobial prophylaxis is discussed separately. (See  <a class="medical medical_review" href="/d/html/1405.html" rel="external">"Prevention of infections in patients with chronic lymphocytic leukemia", section on 'Purine analog therapy'</a> and  <a class="medical medical_review" href="/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia", section on 'Other purine analogs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who develop neutropenic fever require prompt evaluation and immediate administration of parenteral antibiotics tailored to the prominent organisms and resistance patterns of the institution. (See  <a class="medical medical_review" href="/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The use of granulocyte colony-stimulating factors must take into account the expected incidence of neutropenia and patient age. (See  <a class="medical medical_review" href="/d/html/16889.html" rel="external">"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prevention of infection through vaccination is important in patients with HCL. However, many patients with impaired immunity are unable to mount a protective immune response to active vaccination, and immunization with live virus vaccines may result in unchecked proliferation of attenuated strains. Most patients with HCL should be vaccinated with inactivated vaccines (eg, <a class="drug drug_general" data-topicid="9055" href="/d/drug information/9055.html" rel="external">inactivated influenza vaccine</a>), as indicated. Those receiving chemotherapy should <strong>not</strong> receive live virus vaccines (eg, vaccines for varicella; measles, mumps, rubella; measles, mumps, rubella, and varicella). Further details, including the appropriate timing of vaccination in patients with cancer, are discussed separately. (See  <a class="medical medical_review" href="/d/html/3899.html" rel="external">"Immunizations in adults with cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with serologic evidence of hepatitis B virus (HBV) infection (HBsAg-positive or anti-HBc-positive) are at risk for HBV reactivation and severe hepatitis if they receive immunosuppressive therapy. (See  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients previously treated with purine analogs should receive irradiated blood products, if transfusion is indicated, to prevent transfusion-associated graft-versus-host disease. (See  <a class="medical medical_review" href="/d/html/7939.html" rel="external">"Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Irradiation'</a>.)</p><p></p><p class="headingAnchor" id="H1048342719"><span class="h2">Variant hairy cell leukemia</span><span class="headingEndMark"> — </span>HCL variant (HCL-v) is a rare chronic B cell lymphoid neoplasm that was previously thought to be a subtype of HCL but is now considered to be an entity that is biologically distinct from HCL. (See  <a class="medical medical_review" href="/d/html/4532.html" rel="external">"Clinical features and diagnosis of hairy cell leukemia", section on 'HCL variant'</a>.)</p><p>For most patients with HCL-v, we suggest either five daily infusions of <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> or seven days of continuous infusion cladribine, each followed approximately one month later by eight weekly treatments of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>. The choice between the five- and seven-day schedules can be based on feasibility in the clinic and clinician preferences. We administer the rituximab as consolidation rather than concurrently with the cladribine as cladribine frequently causes fever, which can complicate concurrent rituximab administration. Those who achieve normal peripheral blood counts are observed until progression. (See <a class="local">'Administration'</a> below.)</p><p>Support for <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> comes from small prospective studies that report complete remission rates (CR) of at least 90 percent [<a href="#rid6">6-8</a>]. In the largest of these, 20 patients with HCL-v were treated with five daily infusions of cladribine plus eight weekly infusions of rituximab beginning on day 1 of cladribine [<a href="#rid8">8</a>]. Patients received a second eight-week course of rituximab if and when their blood had detectable minimal residual disease (MRD) at least six months after the first course. CR was achieved in 70 percent at four weeks and in 95 percent at six months. Eleven patients received a second course of rituximab. After a median follow-up of 70 months, estimated five-year progression-free survival (PFS) and overall survival (OS) were 63 and 74 percent, respectively. PFS and OS were shorter for HCL-v with mutated <em>TP53</em> and/or detectable MRD at six months.</p><p>In contrast, most cases of HCL-v are poorly responsive or resistant to treatment with purine analogs alone and/or splenectomy [<a href="#rid9">9-11</a>]. </p><p class="headingAnchor" id="H3"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H1527367337"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>Our initial approach to treatment is generally consistent with that proposed by an international consensus guideline supported by the Hairy Cell Leukemia Foundation [<a href="#rid1">1</a>], the British Society for Haematology [<a href="#rid12">12</a>], and the National Comprehensive Cancer Network [<a href="#rid13">13</a>].</p><p>When selecting a management strategy  (<a class="graphic graphic_algorithm graphicRef134914" href="/d/graphic/134914.html" rel="external">algorithm 1</a>), the following principles apply:</p><p class="bulletIndent1"><span class="glyph">●</span>Therapy should be reserved for patients with symptomatic disease since asymptomatic patients may do well without therapy and treatment has potential short- and long-term complications. (See <a class="local">'Indications for treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Purine analogs (ie, <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> or <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a>) are the preferred initial treatment for most patients with symptomatic HCL and normal kidney function. Durable responses are seen in &gt;90 percent of patients with a median progression-free survival (PFS) of 9 to 11 years. Because of ease of administration, we often prefer a single cycle of cladribine. For most patients with HCL, we offer either five daily infusions of cladribine or seven days of continuous infusion cladribine. The choice between the five- and seven-day schedules can be based on feasibility in the clinic and clinician preferences. Following initial treatment with cladribine, we offer a short course of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> consolidation. (See <a class="local">'Purine analogs'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with an active infection are treated with antimicrobials in an attempt to control the infection prior to starting a purine analog. (See <a class="local">'Infections'</a> above.)</p><p></p><p class="bulletIndent1">If it is not possible to control the infection and there is need for immediate treatment, alternative therapies or dosing not associated with myelosuppression (eg, low dose <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> [<a href="#rid14">14,15</a>], <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>) may be offered until the infection is controlled. Treatment with standard dose purine analogs is not suggested in the setting of active infection since it is associated with a decline in neutrophils prior to hematologic recovery. (See <a class="local">'BRAF inhibition (vemurafenib or dabrafenib)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Purine analogs must be used with caution in patients with kidney impairment. There are no dose adjustments provided in the manufacturer's labeling and these agents have not been adequately studied in this population. Some authorities suggest dose adjustments for <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> (75 percent dose for creatinine clearance [CrCl] 10 to 50 mL/min; 50 percent dose for CrCl &lt;10 mL/min).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Splenectomy may be offered as a palliative therapy in patients with symptomatic splenomegaly (massive enlargement, pain, infarction, rupture); as a temporizing measure in symptomatic pregnant women; or as a salvage therapy in patients with pancytopenia which is still present after other therapies. (See <a class="local">'Splenectomy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the immediate post-treatment period, patients are monitored with serial complete blood counts for count recovery and clinically for fever and signs/symptoms of infection. Response should be formally assessed four to six months after the conclusion of primary therapy. (See <a class="local">'Response assessment'</a> below.)</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Purine analogs</span><span class="headingEndMark"> — </span>The purine analogs <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> (2'-deoxycoformycin, 2'-DCF) and <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> (2-chlorodeoxyadenosine, 2-CdA) are naturally targeted to lymphocytes and are cytotoxic to both resting and dividing cells. Both drugs induce durable complete remissions (CR) in the overwhelming majority of patients with HCL. Equally high rates of durable CRs are achieved with these two agents in both untreated and previously treated patients [<a href="#rid16">16,17</a>] and those with large or minimal tumor burdens. For these reasons, these agents are the initial treatment of choice for patients with HCL. There are no large series of patients with HCL treated with the other major purine analog <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>.</p><p class="headingAnchor" id="H2938010797"><span class="h3">Choice of purine analog</span><span class="headingEndMark"> — </span>The choice between <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> and <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> must take into account the ease of administration and patient-related factors. For most patients, we prefer cladribine because of the shorter duration of therapy required (five to seven days versus several months), and general tolerability. Pentostatin has a boxed warning for severe renal toxicities with doses higher than recommended; do not exceed the recommended dose. Serum creatinine elevations occurring at recommended doses are usually minor and reversible.</p><p>The majority of patients achieve durable remissions with either multiple cycles of <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> or a single cycle of <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> [<a href="#rid18">18,19</a>]. In one study of 233 patients followed for a median period of 16 years, cladribine and pentostatin resulted in similar overall response rates (100 versus 96 percent), rates of CR (76 versus 82 percent), and 10-year survivals (100 versus 96 percent) [<a href="#rid16">16,17</a>]. Patients achieving a CR with either agent showed significantly longer median disease-free survival (DFS) than those attaining only a partial remission (PR; not reached at 14 years versus 5.5 years).</p><p>The following illustrates the differences in administration:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">Cladribine</a> is administered with a defined endpoint. It is most often given as a two-hour infusion for five daily doses or as a continuous infusion over seven days. Cladribine should not be used in patients with active infection as trials excluded these patients. (See <a class="local">'Cladribine'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">Pentostatin</a> is administered intravenously once every two weeks as an outpatient. Pentostatin dose can be titrated to reduce the depth and duration of myelosuppression. Pentostatin has been used with active infection [<a href="#rid14">14,15</a>]. (See <a class="local">'Pentostatin'</a> below.)</p><p></p><p class="headingAnchor" id="H5"><span class="h3">Cladribine</span></p><p class="headingAnchor" id="H2531529720"><span class="h4">Administration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">Cladribine</a> (2-CdA) is our preferred initial therapy for most patients with previously untreated HCL. Cladribine should not be used in patients with active infection as trials excluded these patients and cladribine is myelosuppressive. Cladribine is administered on a defined schedule. For most patients with HCL, we offer five daily infusions of cladribine or seven days of continuous infusion cladribine. Following initial treatment with cladribine, we offer a short course of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> consolidation.</p><p>Various regimens have been used in clinical trials and the following two options are widely accepted:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">Cladribine</a> administered as a continuous intravenous infusion 0.1 mg/kg per day for seven days [<a href="#rid20">20-26</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">Cladribine</a> 0.14 mg/kg/day intravenously over two hours once per day for five days [<a href="#rid27">27-29</a>]</p><p></p><p>Alternative off-label routes and schedules of administration of <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> have included weekly two-hour infusions [<a href="#rid30">30,31</a>], oral administration [<a href="#rid27">27,28,32</a>], and subcutaneous administration [<a href="#rid27">27,28,33,34</a>]. Subcutaneous administration appears to be safe and to achieve drug levels similar to those achieved with intravenous administration [<a href="#rid27">27,28,34</a>]. Although prospective trials that used this route report excellent survival (similar to the normal population), there were relatively high rates of second primary malignancy (20 percent after a median of 5.7 years) and need for second-line treatment (required by 24 percent after a median of five years) [<a href="#rid33">33</a>].</p><p>The seven-day infusion of <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> may be more myelosuppressive but has added convenience since it can be administered as an outpatient with a portable pump. The five daily infusions require more frequent visits to the clinic but allow for an in-person assessment of toxicity by the clinical team. As described below, deeper responses have been achieved using sequential cladribine followed by <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>; it is not known yet whether this strategy will lead to greater long-term DFS compared with cladribine alone. Following initial treatment with cladribine, we offer a short course of rituximab consolidation. (See <a class="local">'Rituximab'</a> below.)</p><p>Fever occurs in the majority of patients treated with <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a>, coinciding with a rapid decline in the number of circulating hairy cells and neutrophils [<a href="#rid35">35</a>]. In some series, no viral, fungal, or other opportunistic infections were observed other than a single case of dermatomal herpes zoster 16 months after treatment. Infections are rarely documented, and it is believed that the fever may reflect cytokine release from hairy cells.</p><p>A phase II trial of granulocyte colony-stimulating factor (G-CSF) explored the relationship between cladribine-induced fever and neutropenia [<a href="#rid35">35</a>]. Treatment with G-CSF shortened the period of neutropenia, as compared with historical controls treated with <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> alone. However, the incidence of febrile patients, number of febrile days, or frequency of admission for treatment with antibiotics was not changed. These data support the hypothesis that most fever is cytokine-mediated and not due to infection.</p><p><a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">Cladribine</a> therapy may be associated with the development of unexpected foci of hypoplasia and aplasia in bone marrow biopsies performed as part of their evaluation [<a href="#rid36">36</a>]. These foci are present in patients in CR with normal peripheral blood counts; their long-term significance is unclear [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H1865786617"><span class="h4">Efficacy</span></p><p class="headingAnchor" id="H116644023"><span class="h5">Single-agent cladribine</span><span class="headingEndMark"> — </span>A single cycle of <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> will achieve a durable remission in the vast majority of patients with HCL. Cladribine has not been evaluated in randomized trials. Support for its use comes from case series and retrospective analyses.</p><p class="bulletIndent1"><span class="glyph">●</span>The largest single institution experience with <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> (0.1 mg/kg per day for seven days by continuous intravenous infusion) consisted of 349 evaluable patients with previously treated or untreated HCL [<a href="#rid23">23,24</a>]. The CR and PR rates were 91 and 7 percent, respectively. At four years, the overall survival (OS) was 96 percent; the relapse rates for patients achieving CR and PR were 16 and 54 percent, respectively. Of the 53 patients in first relapse after a cladribine-induced remission, retreatment with cladribine yielded CR and PR rates of 62 and 26 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extended follow-up from the same institution of 88 young adults (≤40 years) treated with <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> and followed for a median of 21 years reported an 88 percent CR rate with a median duration of CR of 57 months (range 7 to 246 months) [<a href="#rid37">37</a>]. A PR was achieved in 12 percent with a median duration of response of 20 months (range 7 to 108 months). There was great variation in the length of response and, except for the degree of response (partial versus complete), the study could not identify clinical or pathologic features that were associated with longer or shorter duration of response. Data regarding measurable residual disease after treatment were not available. Of interest, the median duration of response in this population of younger adults was shorter than the median duration of response in an age-unrestricted population from the same center (57 versus 98 months, respectively).</p><p></p><p>In most other studies, including our own, 76 to 80 percent of assessable patients with HCL treated with <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> achieved CR, and 7 to 24 percent achieved PR, with minimal toxicity [<a href="#rid16">16,21,22,38</a>]. The majority of patients remained disease-free for a prolonged period of time, with relapse rates of 14 to 20 percent at 24 to 30 months and 36 percent at 9.7 years [<a href="#rid38">38</a>]. PFS and OS at four years have been 72 to 84 percent and 86 to 96 percent, respectively [<a href="#rid21">21,23-25,39,40</a>]. OS in three series, including our own, was 79 to 87 percent after 12 years [<a href="#rid33">33,38,41</a>].</p><p class="headingAnchor" id="H1331872647"><span class="h5">Cladribine plus rituximab</span><span class="headingEndMark"> — </span>As described below, incorporation of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> into the initial therapy deepens responses and results in long remission durations; however, rituximab is also associated with immunosuppression and longer follow-up is needed to confirm superiority in long-term outcomes. Starting four to six weeks after initial treatment with <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a>, we offer four weekly doses of rituximab consolidation.</p><p>In a phase II trial, 59 patients with newly diagnosed HCL requiring treatment received an initial cycle of <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> followed approximately one month later by eight weekly treatments of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid7">7,42,43</a>]. All patients achieved a CR and there were no severe (grade 3/4) toxicities. At a median follow-up of 60 months, the estimated rates of five-year failure-free survival and OS were 95 and 97 percent, respectively. Two patients required subsequent therapy, one for hematologic relapse at 12 months and the other for measurable residual disease (MRD) recurrence at 52 months. One patient died due to an unrelated cancer.</p><p>In a second phase II trial, 68 patients with purine analog-naïve classic HCL requiring treatment were randomly assigned to receive <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> plus concurrent or delayed <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid44">44</a>]. Those assigned to concurrent rituximab received eight weekly doses of rituximab starting on the first day of cladribine. Those assigned to delayed rituximab received rituximab if they had MRD in the blood six months or more after the cladribine. Both treatment groups could receive a second course of rituximab if MRD was detected in the blood six months or more after the first rituximab. When compared with a delayed rituximab strategy, concurrent rituximab resulted in:</p><p class="bulletIndent1"><span class="glyph">●</span>Higher rates of blood MRD negativity at six months (100 versus 50 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fewer patients requiring two courses of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (3 versus 18 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher likelihood of maintaining MRD negativity long term (94 versus 12 percent with a median follow-up of 96 months). Ten patients maintained MRD negativity for more than five years after <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> monotherapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher rates of grade 3 or 4 thrombocytopenia (59 versus 9 percent) and need for platelet transfusions (35 versus 0 percent).</p><p></p><p>This study design raises several questions regarding the timing of treatment and the schedule and number of doses of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>. The study compared concurrent treatment versus treatment of blood MRD-positive disease six months after initial therapy. The latter arm is more reflective of treatment of resistant disease rather than consolidation of initial therapy. The design also used eight doses of concurrent rituximab rather than four doses of consolidation rituximab. Concurrent use of rituximab with <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> adds toxicity. In addition, infusion-related reactions seen with rituximab may be confounded by the fever commonly seen with cladribine alone. It is also unlikely that eight doses of rituximab are necessary given the long periods of disease control seen with four doses when given as consolidation.</p><p class="headingAnchor" id="H6"><span class="h3">Pentostatin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">Pentostatin</a> is an acceptable alternative to <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> for the initial treatment of HCL given its similar efficacy. When compared with interferon alfa (IFNa), pentostatin results in superior response rates and longer remissions.</p><p class="headingAnchor" id="H3080387357"><span class="h4">Administration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">Pentostatin</a> is administered as 4 mg/m<sup>2</sup> intravenously (IV) once every two weeks until maximal response. Infusions can be given in the outpatient setting. The dose of pentostatin can be titrated to reduce the depth and duration of myelosuppression. Unlike <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a>, pentostatin has been used with active infection [<a href="#rid14">14,15</a>].</p><p><a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">Pentostatin</a> has a boxed warning for severe renal toxicities with doses higher than recommended; do not exceed the recommended dose. Serum creatinine elevations occurring at recommended doses are usually minor and reversible. Data regarding risk of nausea or emesis are limited, but risk appears to be low.</p><p>While clinicians often administer two consolidation doses of <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> after induction is complete, there is no evidence that this is necessary. Failure to obtain clinical evidence of an objective response by six months should lead to a change in therapy. Patients who show objective evidence of response by six months can be treated for up to a year in an attempt to achieve an optimal response.</p><p><a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">Pentostatin</a> is associated with a decrease in the total lymphocyte count, with a reduction in T cells proportionately greater than that for B cells or natural killer cells [<a href="#rid45">45</a>]. Absolute numbers of CD4+ and CD8+ cells fall to less than 200 cells/microL for at least six months after pentostatin is discontinued. In two studies, the median time to recovery of CD4+ cell counts following cessation of therapy was 54 months with pentostatin [<a href="#rid46">46</a>] and 40 months with <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> [<a href="#rid40">40</a>].</p><p>Despite this degree of immunosuppression, opportunistic infections, other than an occasional case of herpes zoster, are uncommon unless purine analog treatment is associated with concomitant glucocorticoid exposure [<a href="#rid47">47</a>]. Prophylaxis against <em>Pneumocystis carinii</em> pneumonia may be reasonable if glucocorticoids are being given for a separate indication. (See  <a class="medical medical_review" href="/d/html/1405.html" rel="external">"Prevention of infections in patients with chronic lymphocytic leukemia"</a> and  <a class="medical medical_review" href="/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia", section on 'Other purine analogs'</a>.)</p><p class="headingAnchor" id="H3647223422"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>The majority of patients achieve durable remissions with either multiple cycles of <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> or a single cycle of <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a>. When compared with IFNa, pentostatin results in superior response rates and longer remissions. In addition, pentostatin is usually effective in patients who are refractory to treatment with IFNa [<a href="#rid48">48</a>].</p><p><a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">Pentostatin</a> was the first drug reported that induced a high rate of CRs in HCL [<a href="#rid49">49,50</a>]. Trials have used a variety of doses and schedules [<a href="#rid14">14,32,48-58</a>]. Higher doses have been associated with similar response rates, but greater toxicity. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In an study of 50 patients with HCL treated with <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> (5 mg/m<sup>2</sup> per day for two consecutive days every two weeks until maximum response), overall response rate and CR rate were 84 and 64 percent, respectively, with the majority of patients achieving maximal response within six months [<a href="#rid52">52</a>]. Toxicities were moderate and included nausea, vomiting, skin rash, and conjunctivitis, as well as significant neurologic toxicities in four patients. "Life-threatening" neutropenia occurred in 70 percent of patients; however, this was limited to the first two to three cycles of therapy. Mortality as a result of therapy was attributable to infection in 6 percent of patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, CR was attained in 20 of 23 patients (87 percent) treated with <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> (4 mg/m<sup>2</sup> every other week) with infrequent infections and no treatment-related deaths [<a href="#rid32">32</a>]. CD4+ cells were significantly, but only temporarily, decreased after treatment, with no opportunistic infections or second malignancies being noted after two years of follow-up.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another series evaluated a regimen of <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> at 4 mg/m<sup>2</sup> IV weekly for three consecutive weeks, with therapy repeated every eight weeks [<a href="#rid56">56</a>]. CR was achieved in 25 of 28 patients (89 percent) after completion of two cycles of therapy. Transient neutropenia occurred only during the first cycle and 12 patients developed fever and/or infection; there were no deaths.</p><p></p><p>The relative efficacy of <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> and IFNa was evaluated in a prospective intergroup study that randomly assigned 313 patients with HCL to receive either pentostatin (4 mg/m<sup>2</sup> IV every two weeks for six months) or IFNa (3 million units subcutaneously three times per week) [<a href="#rid14">14</a>]. Pentostatin therapy was associated with higher rates of confirmed CR (76 versus 11 percent) and confirmed CR or PR (79 versus 38 percent) and a longer median relapse-free survival (not reached versus 20 months after a median follow-up of 57 months). Survival outcomes were not significantly different between treatment arms, although this analysis was complicated by the cross-over design of the study. Estimated OS and relapse-free survival of patients achieving CR with pentostatin were 87 and 76 percent, respectively [<a href="#rid59">59</a>].</p><p>At a median follow-up of over nine years, 83 percent of patients treated with <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> on this protocol were still alive, and only 18 percent of those who achieved CR have relapsed [<a href="#rid59">59</a>]. Of the 40 deaths, two were related to HCL; the mortality rate for the cohort of pentostatin-treated patients was similar to age- and sex-specific mortality in the United States.</p><p class="headingAnchor" id="H10"><span class="h2">Splenectomy</span><span class="headingEndMark"> — </span>Splenectomy is not routinely used for patients with HCL. Possible indications for splenectomy in HCL include:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic splenomegaly (massive enlargement, pain, infarction, rupture)</p><p class="bulletIndent1"><span class="glyph">●</span>Pancytopenia due to splenic sequestration that is still present after other treatments [<a href="#rid60">60</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>As a temporizing measure in symptomatic pregnant women [<a href="#rid61">61</a>]</p><p></p><p>Highly effective therapy with purine analogs generally obviates the need for splenectomy in other settings. (See <a class="local">'Purine analogs'</a> above.)</p><p>Removal of the spleen was the first effective therapy for HCL [<a href="#rid62">62-64</a>]. Although splenectomy does not produce pathologic remissions, peripheral blood counts return to normal in approximately 40 to 70 percent of patients [<a href="#rid62">62</a>]. The response to splenectomy is maintained for a median of 20 months, approximately one-half have disease progression within five years, and the OS at five years is 60 to 70 percent [<a href="#rid62">62,65</a>].</p><p class="headingAnchor" id="H3485882837"><span class="h1">RESPONSE ASSESSMENT</span><span class="headingEndMark"> — </span>Following initial treatment, patients should be evaluated to determine the response to therapy. This evaluation includes a complete physical examination, including an evaluation of spleen size, complete blood count with differential, and a bone marrow biopsy  (<a class="graphic graphic_table graphicRef112194" href="/d/graphic/112194.html" rel="external">table 1</a>). Although post-treatment bone marrow biopsy is not mandatory outside of a clinical trial, it is required to document a complete response (CR) and has prognostic value.</p><p>The bone marrow biopsy looks for normal hematopoiesis and the eradication of the leukemic cells. Following the completion of therapy, there can be delayed and continuing improvement. Bone marrow biopsy should be delayed for four to six months following the completion of <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> therapy. Following <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a>, bone marrow biopsy is performed when there is near normalization of hematologic parameters.</p><p>Initial treatment aims to achieve a CR defined as [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Near normalization of peripheral blood counts: hemoglobin &gt;11 g/dL (without transfusion); platelets &gt;100,000/microL; absolute neutrophil count &gt;1500/microL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Regression of splenomegaly on physical examination. Radiographic assessment of spleen size is not necessary for clinical practice.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absence of morphologic evidence of HCL on both the peripheral blood smear and the bone marrow examination.</p><p></p><p>Measurable residual disease (MRD, also called "minimal residual disease") is defined as HCL infiltrates recognizable by immunohistochemical stains, but not by conventional stains. Depending on the criteria used, 13 to 53 percent of patients in apparent CR have evidence of MRD, which may or may not predict future relapse [<a href="#rid66">66-69</a>]. MRD has also been detected using polymerase chain reaction and flow cytometry [<a href="#rid70">70-72</a>].</p><p>The peripheral blood counts required for CR are slightly lower than normal because they account for the recovery period needed following exposure to purine analogs. The lymphocyte count, including lymphocyte subsets, may be reduced for a long time after exposure to purine analogs [<a href="#rid40">40</a>].</p><p>Patients with a partial response may remain asymptomatic for many years without further therapy. Alternatively, a second course of <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a>, an alternative purine analog, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> therapy, or combination therapy with rituximab plus a purine analog may be offered [<a href="#rid19">19,42,73,74</a>]. The extent of remaining MRD that may impact the potential for relapse must be balanced by the extent of therapy being used to achieve this end.</p><p>Those with stable or progressive disease need further therapy. Decreases in hematologic parameters may be due to disease progression or the myelosuppression of therapy. A decline in blood counts due to chemotherapy will recover with observation.</p><p class="headingAnchor" id="H12"><span class="h1">TREATMENT OF RESISTANT OR RELAPSED DISEASE</span></p><p class="headingAnchor" id="H13"><span class="h2">Resistant disease</span><span class="headingEndMark"> — </span>The vast majority of patients treated with purine analogs will achieve a response, but up to 4 percent of patients have stable or progressive disease and up to 20 percent achieve only a partial remission (PR) [<a href="#rid16">16,17,19,38</a>]. For patients with HCL resistant to treatment with a purine analog, we suggest switching to an alternative purine analog (ie, <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> in those who have received <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a>, and vice versa) or off-label <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>. (See <a class="local">'BRAF inhibition (vemurafenib or dabrafenib)'</a> below.)</p><p>Patients with HCL resistant to two or more therapies are candidates for <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>, <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, single-agent rituximab, splenectomy, or other investigational therapies.</p><p class="headingAnchor" id="H15"><span class="h2">Relapsed disease</span><span class="headingEndMark"> — </span>Criteria for retreatment are the same as those used for initial treatment. Retreatment is not necessary simply for the reappearance of hairy cells in the peripheral blood or bone marrow by morphologic or immunophenotypic/immunohistochemical techniques. The decision to treat must weigh the potential toxicity of treatment. (See <a class="local">'Indications for treatment'</a> above.)</p><p>Our preferred therapy for patients with relapsed HCL depends in part on the length of response to initial therapy  (<a class="graphic graphic_algorithm graphicRef134914" href="/d/graphic/134914.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a previous remission lasting &gt;24 months, we suggest retreatment with the previously effective purine analog or alternative purine analog (ie, <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> in those who have received <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a>, and vice versa), each followed by <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>. (See <a class="local">'Purine analogs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with an initial remission &lt;24 months, we re-evaluate the accuracy of the original diagnosis. We do not retreat with the initial therapy. Options include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Off-label <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>. (See <a class="local">'BRAF inhibition (vemurafenib or dabrafenib)'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Alternative purine analog (ie, <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> in those who have received <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a>, and vice versa). (See <a class="local">'Pentostatin'</a> above.) </p><p></p><p class="bulletIndent1">In addition, single-agent <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> is a reasonable alternative for those relapsing &lt;24 months after a purine analog alone. (See <a class="local">'Rituximab'</a> below.)</p><p></p><p>Patients are likely to experience serial relapses. Older therapeutic approaches (eg, interferon alfa, splenectomy) may still offer benefit in this setting, but a clinical trial would be preferred.</p><p>Retreatment with a second cycle of <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> or <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> leads to a second complete remission (CR) in up to 70 percent of patients [<a href="#rid16">16,17,21,23,37,38</a>]. In one study, the probability of achieving a CR was not affected by whether the patient was retreated with the same purine analog (71 percent) or switched to the alternative one (68 percent) [<a href="#rid17">17</a>].</p><p>While overall response rates are 97 to 100 percent after second- and third-line treatment with the purine analogs, the rates of CR as well as the lengths of disease-free survival (DFS) become progressively shorter with each course of therapy. In one study, median DFS after an initial course of a purine analog was not reached at 14 years, and the median DFS after second- and third-line treatment with these agents was 7.5 and 4 years, respectively [<a href="#rid17">17</a>]. In our experience, retreatment with <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> occasionally leads to long periods of myelosuppression and cytopenias.</p><p class="headingAnchor" id="H16"><span class="h2">Targeted therapies</span></p><p class="headingAnchor" id="H17"><span class="h3">Rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> can be incorporated into the treatment of HCL as part of initial therapy (ie, rituximab consolidation) or at the time of progression. While usually offered in combination, single agent rituximab is an option for patients with HCL progressing &lt;24 months after a purine analog alone. The use of single-agent rituximab has yielded mixed results in clinical trials. Toxicity in all of these trials has been minimal. The following is an overview of some of the studies that have evaluated this treatment approach. Rituximab consolidation after initial therapy is discussed separately. (See <a class="local">'Cladribine plus rituximab'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>A phase II study of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> in 24 patients with relapsed disease after treatment with <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> demonstrated overall response rates of 24 percent (three complete, three partial) [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A number of small studies have reported higher overall (64 to 100 percent) and complete (53 to 92 percent) responses, as well as overall molecular response rates as high as 70 percent [<a href="#rid16">16,71,76-78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective review evaluated <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> or <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> combined concurrently or sequentially with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> as second-line therapy [<a href="#rid79">79</a>]. All eight patients responded to therapy with seven CRs. At a median follow-up of 29 months, only one patient had developed recurrent disease. The relative benefits of concurrent or sequential cladribine followed by rituximab will require further study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective review of 15 patients with relapsed or refractory HCL treated with <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> reported disease response in all evaluable patients (13 patients) [<a href="#rid80">80</a>]. Three patients achieved measurable residual disease (MRD) negativity. After a median follow-up of 35 months, 14 patients remained progression-free, while one succumbed to complications of the disease. It is not clear that fludarabine provided additional benefit to the rituximab therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A phase II trial evaluated five days of intravenous <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> followed approximately one month later with eight weekly treatments of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> in 14 patients with relapsed HCL requiring treatment [<a href="#rid7">7</a>]. There were no severe (grade 3/4) events, and all patients achieved a CR. No relapses or deaths had occurred after a median follow-up of 60 months.</p><p></p><p class="headingAnchor" id="H1074089130"><span class="h3">BRAF inhibition (vemurafenib or dabrafenib)</span><span class="headingEndMark"> — </span>We reserve the off-label use of <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> for patients with an unsatisfactory response to or progression within 24 months of initial treatment with a purine analog  (<a class="graphic graphic_algorithm graphicRef134914" href="/d/graphic/134914.html" rel="external">algorithm 1</a>). When used as single agents, BRAF inhibitors can induce partial, transient responses in HCL with <em>BRAF</em> mutations. The addition of rituximab to vemurafenib appears to result in faster, deeper responses with longer remissions, although further data are needed to confirm efficacy and clarify the optimal dosing and schedule. The addition of <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a> can result in prolonged remissions, although with substantially increased toxicity. Repeat treatment with a BRAF inhibitor can result in a second response at relapse. BRAF inhibitors are likely not effective in patients with the HCL-variant since such cases do not usually express the <em>BRAF</em> mutation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vemurafenib</strong><strong> plus </strong><strong>rituximab</strong> – A single center, phase 2 trial evaluated the combination of <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> in 30 patients with relapsed or refractory HCL after a median of three prior therapies [<a href="#rid81">81</a>]. Two four-week induction cycles of vemurafenib plus rituximab were followed by four additional doses of rituximab consolidation. A CR was achieved in 26 patients (87 percent) and 17 had undetectable minimal residual disease. Among responders, 85 percent were relapse-free after a median follow-up of 34 months. Progression-free survival was 78 percent at 37 months for the larger population. Toxicities were mostly grade 1 or 2 and reflected those of the individual agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vemurafenib</strong><strong> or </strong><strong>dabrafenib</strong><strong> alone</strong> – Small prospective trials have evaluated <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> and <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> as single agents [<a href="#rid82">82-84</a>]. As an example, two phase 2 multicenter studies evaluated the efficacy of vemurafenib (960 mg twice daily) in patients with HCL relapsed after or refractory to treatment with purine analogs [<a href="#rid82">82,84</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the Italian study of 28 patients, the overall response rate was 96 percent (35 percent complete) after a median of eight weeks of treatment. After a median follow-up of 23 months, those with a CR had median relapse-free and treatment-free survivals of 19 and 25 months, respectively. Partial responders had median relapse-free and treatment-free survival times of 6 and 18 months, respectively.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the United States study of 36 patients, the overall response rate was 86 percent (33 percent complete). The median relapse free survival (RFS) was 19 months (range 12.5 to 53.9 months), and independent of depth of response. Estimated four-year overall survival was 86 percent, and significantly worse for those relapsing within one year of treatment. Of the 21 patients who relapsed, 14 patients were retreated with <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>, and 86 percent achieved a complete hematologic response. Median RFS upon retreatment was 12.7 months. Two patients acquired resistance mutations (<em>CDKN2</em> loss and activating <em>KRAS</em> mutation).</p><p></p><p class="bulletIndent1">In a retrospective study of 27 patients treated with either <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> or <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a>, 18 of 20 patients evaluable for response by bone marrow examination demonstrated a complete or partial response (6 CR and 12 PR) [<a href="#rid85">85</a>]. After discontinuation of the BRAF inhibitor, responses were not durable. The median time to next treatment was 12.1 months in the population overall, and 17.6 months in those who achieved CR without detectable minimal residual disease. The doses and durations of both BRAF inhibitors varied. The majority of patients had been previously treated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dabrafenib</strong><strong> plus </strong><strong>trametinib</strong> – The combination of <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a> (an inhibitor of downstream <em>MEK</em>) was evaluated in an open-label, nonrandomized, phase 2 basket study (ROAR) of patients with <em>BRAF</em>V600E-mutant rare cancers [<a href="#rid86">86,87</a>]. The study included 55 adults with HCL, all of whom were either refractory to first-line treatment with a purine analog or relapsed after at least two prior lines of treatment. Treatment was continued until unacceptable toxicity, disease progression, or death. Responses were seen in 89 percent and 66 percent attained a CR. After a median follow-up of 43 months, the median duration of response was not reached and 60 percent continued on study treatment. The estimated 24-month PFS and OS were 94 percent and 95 percent, respectively. The most common treatment related adverse events were fever (58 percent), chills (47 percent), and hyperglycemia (40 percent). Grade 3 or higher adverse events were reported in 64 percent. A majority required dose reduction (53 percent), dose interruption (69 percent), or permanent discontinuation (22 percent) of one or both drugs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicities</strong> – Most toxicities with BRAF inhibitors are mild (grade 1 or 2), although dose reductions secondary to toxicity are common. The most common toxicities included rash, photosensitivity, arthralgias/arthritis, fever, and elevations in liver and pancreatic enzymes. Secondary cutaneous tumors developed in 14 percent, all of which were treated with excision. Squamous cell carcinomas and keratoacanthomas have also been reported. Rarely, <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> has caused abnormal renal function [<a href="#rid82">82</a>]. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Toxicities of BRAF and MEK inhibitors'</a>.)</p><p></p><p class="headingAnchor" id="H983426371"><span class="h3">Venetoclax</span><span class="headingEndMark"> — </span>Initial case reports suggest that the BCL-2 inhibitor <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> is active in multiply relapsed HCL [<a href="#rid88">88,89</a>].</p><p>In a single center report, five of six patients with multiply relapsed HCL responded to treatment with <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> with or without <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid88">88</a>]. Among these five, progression-free survival ranged from 23 to &gt;53 months. The main toxicities were worsening neutropenia, accompanied in some by fever and/or infection. All patients had received <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> plus rituximab as their most recent therapy with progression within 6 to 37 months. While these initial data suggest that venetoclax has activity in HCL, further study needed to better assess efficacy.</p><p class="headingAnchor" id="H3927437916"><span class="h3">Ibrutinib</span><span class="headingEndMark"> — </span>Initial studies have suggested modest activity of the Bruton tyrosine kinase inhibitor <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> [<a href="#rid90">90-92</a>]. While some experts offer off-label ibrutinib to patients with multiply relapsed HCL, we favor other treatments given the low response rate with ibrutinib.</p><p>In a phase 2 trial of <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> in 37 patients with HCL (28 classical HCL, 9 variant HCL), the overall response rate was 36 percent at 48 weeks and the estimated progression-free survival was 73 percent at 36 months [<a href="#rid92">92</a>]. Response rates appeared to be similar in those with classical HCL and those with variant HCL. Toxicities were similar to those seen with this drug in other populations.</p><p class="headingAnchor" id="H249471050"><span class="h3">Moxetumomab pasudotox</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="119041" href="/d/drug information/119041.html" rel="external">Moxetumomab pasudotox</a> is being permanently discontinued by the manufacturer effective July 2023 and product supply will not be available after August 2023 [<a href="#rid93">93</a>]. The decision was informed by the low clinical uptake and availability of alternative agents and <strong>not</strong> safety or efficacy concerns. Clinicians should seek alternative therapies for those already receiving moxetumomab pasudotox and avoid starting moxetumomab pasudotox in new patients.</p><p><a class="drug drug_general" data-topicid="119041" href="/d/drug information/119041.html" rel="external">Moxetumomab pasudotox</a> is a pseudomonas exotoxin-linked recombinant anti-CD22 antibody that has shown high response rates in patients with previously treated HCL, but not in those with HCL-variant [<a href="#rid94">94-101</a>]. Toxicities are mostly mild (grade 1 or 2) and include cytokine release syndrome (fever, hypotension, myalgia or arthralgia), edema, gastrointestinal distress, transient hypoalbuminemia, and elevated aminotransferase levels. Severe toxicities are uncommon and reversible, but potentially life threatening, and include capillary leak syndrome and hemolytic uremia syndrome.</p><p>Administration of <a class="drug drug_general" data-topicid="119041" href="/d/drug information/119041.html" rel="external">moxetumomab pasudotox</a> is complicated and includes hydration, premedication for infusion-related reactions, and monitoring for renal toxicity, electrolyte abnormalities, capillary leak syndrome, and hemolytic uremic syndrome.</p><p class="headingAnchor" id="H10318036"><span class="h1">CLINICAL TRIALS AND INVESTIGATIONAL THERAPIES</span><span class="headingEndMark"> — </span>Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=4535" target="_blank">www.clinicaltrials.gov</a>).</p><p>Many agents are under active investigation or in development. These include combinations of agents already used in HCL, agents approved for other diseases, and other novel agents. Some of these are described in the sections above. (See <a class="local">'Targeted therapies'</a> above.)</p><p class="headingAnchor" id="H21"><span class="h1">SECOND MALIGNANCIES</span><span class="headingEndMark"> — </span>Patients should be encouraged to follow normal recommendations for cancer screening, including routine careful follow-up with a dermatologist.</p><p>There are conflicting data on the risk of second malignancies following therapy for HCL [<a href="#rid59">59,102-109</a>]. The range of findings can be illustrated by the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 117 patients with HCL, there were 44 second malignancies in 36 patients; the majority being nonhematologic [<a href="#rid104">104</a>]. Ninety percent confidence intervals for the relative risk of second malignancies varied widely, being 0.2 to 3.8 for splenectomy, 0.6 to 5.7 for purine analogs, 1.6 to 4.3 for interferon followed by purine analogs, and 1.6 to 8.4 for interferon alone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 358 patients with HCL treated with <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a>, second malignancies, only one of which was hematologic, were noted in 8 percent (observed-to-expected ratio [OER] 1.9; 95% CI 1.2-2.7) [<a href="#rid23">23,24</a>]. A similar OER for second malignancies of 1.5 for cladribine and 1.4 for <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> was noted in another series of more than 1300 patients [<a href="#rid105">105</a>]. These ratios are similar to those reported in HCL before the purine analog era [<a href="#rid105">105</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Italian Cooperative Group for the Study of Hairy Cell Leukemia observed a cumulative risk for development of a second malignancy of 14 percent at 15 years, similar to the expected rate (standard incidence ratio [SIR] of 1.01) [<a href="#rid106">106</a>]. However, the SIR for non-Hodgkin lymphoma was higher than expected, at 5.3. Use of interferon did not affect the incidence of second malignancies in this group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Data on 3104 patients with HCL reported to 16 population-based registries in the SEER Program indicated a statistically increased incidence of second cancers compared with the general population (SIR 1.2; 95% CI 1.1-1.4), especially for Hodgkin lymphoma (SIR 6.6), non-Hodgkin lymphoma (SIR 5.0), and thyroid cancer (SIR 3.6) [<a href="#rid107">107</a>]. The cumulative probability of all second cancers was 32 percent at 25 years following the diagnosis of HCL. It was estimated that, among 1000 HCL patients, a total excess of 3.4 cancers might be observed per year (ie, 34/10,000).</p><p></p><p class="headingAnchor" id="H22"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Without treatment, the median survival is approximately four years [<a href="#rid110">110</a>]. While treatment is not curative, survival rates with modern therapy are only slightly lower than the general population.</p><p>The prognosis of patients with HCL was evaluated in an analysis of the Surveillance Epidemiology and End Results (SEER) database that included over 3300 patients diagnosed with HCL between 1973 and 2008 [<a href="#rid111">111</a>]. Over this time period, the age-adjusted risk of death decreased by 85 percent, with the greatest improvement seen in younger patients who have survival rates only slightly lower than the general population. Older age and African American ethnicity were independent predictors of higher mortality.</p><p>In an attempt to address the issue of quality of life in patients, a questionnaire was sent to individuals with a prior diagnosis of HCL who had been treated by this author [<a href="#rid112">112</a>]. There was a 61 percent response rate, with the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Lifestyle changes were noted by 40 to 60 percent of respondents (eg, more frequent exercise, healthier diets, a greater appreciation of life, loved ones, and physical health).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>More than 60 percent paid for some aspect of medical care in spite of having health insurance coverage at the time of diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Twelve percent could not obtain health insurance following treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ten of 13 subjects had difficulty obtaining a life insurance policy or were denied coverage.</p><p></p><p class="headingAnchor" id="H23"><span class="h1">ADDITIONAL INFORMATION</span><span class="headingEndMark"> — </span>The Hairy Cell Leukemia Research Foundation is a non-profit, all volunteer, patient-run organization whose primary goal is to provide support and information concerning this disease and its treatment. Information about this foundation can be found at: <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.hairycellleukemia.org%2F&amp;token=sL%2Bp%2BgWoM5K8OZ3TcR7z2ZcNlzxkNLE4ZtaVUv481kpeW8UNnXnS%2FsXs3cXMuofN&amp;TOPIC_ID=4535" target="_blank">www.hairycellleukemia.org</a> [<a href="#rid113">113</a>].</p><p class="headingAnchor" id="H2428843791"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/122002.html" rel="external">"Society guideline links: Hairy cell leukemia"</a>.)</p><p class="headingAnchor" id="H30688534"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/83669.html" rel="external">"Patient education: Hairy cell leukemia (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Observation for asymptomatic patients</strong> – Many patients with hairy cell leukemia (HCL) are asymptomatic and can be observed for months and occasionally years after the diagnosis is established before requiring treatment. There is no clear advantage to early therapy. As the goal of treatment is alleviation of symptoms and cytopenias, we believe that asymptomatic patients with HCL should not be treated. There is a theoretic risk of infection in such patients, occasionally with opportunistic organisms. (See <a class="local">'Asymptomatic patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for treatment</strong> (see <a class="local">'Indications for treatment'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Significant cytopenias; typical peripheral blood counts that warrant treatment include an absolute neutrophil count &lt;1000/microL with repeated infections, symptomatic anemia with a hemoglobin concentration &lt;11.0 g/dL, or bleeding due to a platelet count &lt;100,000/microL</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Symptomatic splenomegaly (common) or adenopathy (uncommon)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Constitutional symptoms (eg, fever, night sweats, fatigue, weight loss)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment</strong> – For most patients, we recommend a purine-analog-based therapy as first-line therapy  (<a class="graphic graphic_algorithm graphicRef134914" href="/d/graphic/134914.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). Because of ease of administration and shorter treatment duration, we prefer <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> over <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a>.</p><p></p><p class="bulletIndent1">Starting four to six weeks after initial treatment with <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a>, we offer four weekly doses of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> consolidation. (See <a class="local">'Choice of purine analog'</a> above.)</p><p></p><p class="bulletIndent1">Patients with an active infection are treated with antimicrobials in an attempt to control the infection prior to starting a purine analog. If it is not possible to control the infection and there is need for immediate treatment, alternative therapies or dosing not associated with myelosuppression (eg, low dose <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a>, off-label <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>) may be offered until the infection is controlled. (See <a class="local">'Infections'</a> above.)</p><p></p><p class="bulletIndent1">Purine analogs must be used with caution in patients with kidney impairment.</p><p></p><p class="bulletIndent1">For the rare patients who do not respond to initial therapy with a purine analog, we suggest switching to an alternative purine analog or off-label <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Resistant disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management at relapse</strong> – The preferred therapy for patients with relapsed HCL depends in part on the length of response to initial therapy  (<a class="graphic graphic_algorithm graphicRef134914" href="/d/graphic/134914.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a previous remission lasting ≥24 months, we suggest treatment with a purine analog followed by <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> rather than a purine analog alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">Cladribine</a> and <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> are equally effective in this setting, leading to a second complete remission in approximately 70 percent of patients and a third complete remission in approximately 50 percent. (See <a class="local">'Purine analogs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with an initial remission &lt;24 months, we re-evaluate the accuracy of the original diagnosis. We do not retreat with the initial therapy. Instead, we offer one of the following: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Off-label <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>. (See <a class="local">'BRAF inhibition (vemurafenib or dabrafenib)'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Alternative purine analog (ie, <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> in those who have received <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a>, and vice versa). (See <a class="local">'Pentostatin'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 2017; 129:553.</a></li><li><a class="nounderline abstract_t">Kraut E. Infectious complications in hairy cell leukemia. Leuk Lymphoma 2011; 52 Suppl 2:50.</a></li><li><a class="nounderline abstract_t">Teodorescu M, Engebjerg MC, Johansen P, et al. Incidence, risk of infection and survival of hairy cell leukaemia in Denmark. Dan Med Bull 2010; 57:A4216.</a></li><li><a class="nounderline abstract_t">Damaj G, Kuhnowski F, Marolleau JP, et al. Risk factors for severe infection in patients with hairy cell leukemia: a long-term study of 73 patients. Eur J Haematol 2009; 83:246.</a></li><li><a class="nounderline abstract_t">Morrison VA. Infections in patients with leukemia and lymphoma. Cancer Treat Res 2014; 161:319.</a></li><li><a class="nounderline abstract_t">Kreitman RJ, Wilson W, Calvo KR, et al. Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia. Clin Cancer Res 2013; 19:6873.</a></li><li><a class="nounderline abstract_t">Chihara D, Kantarjian H, O'Brien S, et al. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol 2016; 174:760.</a></li><li><a class="nounderline abstract_t">Chihara D, Arons E, Stetler-Stevenson M, et al. Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. Blood Adv 2021; 5:4807.</a></li><li><a class="nounderline abstract_t">Robak T. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev 2006; 32:365.</a></li><li><a class="nounderline abstract_t">Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009; 114:4687.</a></li><li><a class="nounderline abstract_t">Robak T. Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev 2011; 37:3.</a></li><li><a class="nounderline abstract_t">Parry-Jones N, Joshi A, Forconi F, et al. Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V). Br J Haematol 2020; 191:730.</a></li><li class="breakAll">https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf (Accessed on October 15, 2020).</li><li><a class="nounderline abstract_t">Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995; 13:974.</a></li><li><a class="nounderline abstract_t">Andritsos LA, Dunavin N, Lozanski G, et al. Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective. Haematologica 2015; 100:e18.</a></li><li><a class="nounderline abstract_t">Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009; 145:733.</a></li><li><a class="nounderline abstract_t">Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer 2005; 104:2442.</a></li><li><a class="nounderline abstract_t">Grever MR. How I treat hairy cell leukemia. Blood 2010; 115:21.</a></li><li><a class="nounderline abstract_t">Dearden CE, Matutes E, Hilditch BL, et al. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. Br J Haematol 1999; 106:515.</a></li><li><a class="nounderline abstract_t">Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990; 322:1117.</a></li><li><a class="nounderline abstract_t">Tallman MS, Hakimian D, Rademaker AW, et al. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood 1996; 88:1954.</a></li><li><a class="nounderline abstract_t">Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol 1997; 15:1138.</a></li><li><a class="nounderline abstract_t">Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92:1918.</a></li><li><a class="nounderline abstract_t">Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003; 21:891.</a></li><li><a class="nounderline abstract_t">Lauria F, Rondelli D, Zinzani PL, et al. Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey. Leukemia 1997; 11:629.</a></li><li><a class="nounderline abstract_t">Cheson BD, Sorensen JM, Vena DA, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998; 16:3007.</a></li><li><a class="nounderline abstract_t">Liliemark J, Albertioni F, Juliusson G, Eksborg S. A limited sampling strategy for estimation of the cladribine plasma area under the concentration versus time curve after intermittent i.v. infusion, s.c. injection, and oral administration. Cancer Chemother Pharmacol 1996; 38:536.</a></li><li><a class="nounderline abstract_t">Saven A, Cheung WK, Smith I, et al. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J Clin Oncol 1996; 14:978.</a></li><li><a class="nounderline abstract_t">Robak T, Błasińska-Morawiec M, Krykowski E, et al. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymphoma 1996; 22:107.</a></li><li><a class="nounderline abstract_t">Lauria F, Bocchia M, Marotta G, et al. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Haematologica 1999; 84:22.</a></li><li><a class="nounderline abstract_t">Robak T, Jamroziak K, Gora-Tybor J, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 2007; 109:3672.</a></li><li><a class="nounderline abstract_t">Juliusson G, Heldal D, Hippe E, et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 1995; 13:989.</a></li><li><a class="nounderline abstract_t">Benz R, Arn K, Andres M, et al. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. Blood Adv 2020; 4:3699.</a></li><li><a class="nounderline abstract_t">Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 1992; 10:1514.</a></li><li><a class="nounderline abstract_t">Saven A, Burian C, Adusumalli J, Koziol JA. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood 1999; 93:2471.</a></li><li><a class="nounderline abstract_t">Siegel RS, Hakimian D, Spies W, et al. Technetium-99m sulfur colloid scanning and correlative magnetic resonance imaging in patients with hairy cell leukemia and hypocellular bone marrow biopsies after 2-chlorodeoxyadenosine. Leuk Lymphoma 1999; 35:171.</a></li><li><a class="nounderline abstract_t">Rosenberg JD, Burian C, Waalen J, Saven A. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood 2014; 123:177.</a></li><li><a class="nounderline abstract_t">Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005; 106:241.</a></li><li><a class="nounderline abstract_t">Piro LD, Ellison DJ, Saven A. The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymphoma 1994; 14 Suppl 1:121.</a></li><li><a class="nounderline abstract_t">Seymour JF, Kurzrock R, Freireich EJ, Estey EH. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 1994; 83:2906.</a></li><li><a class="nounderline abstract_t">Jehn U, Bartl R, Dietzfelbinger H, et al. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004; 18:1476.</a></li><li><a class="nounderline abstract_t">Ravandi F, O'Brien S, Jorgensen J, et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 2011; 118:3818.</a></li><li><a class="nounderline abstract_t">Ravandi F, Jorgensen JL, O'Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006; 107:4658.</a></li><li><a class="nounderline abstract_t">Chihara D, Arons E, Stetler-Stevenson M, et al. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. J Clin Oncol 2020; 38:1527.</a></li><li><a class="nounderline abstract_t">Urba WJ, Baseler MW, Kopp WC, et al. Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia. Blood 1989; 73:38.</a></li><li><a class="nounderline abstract_t">Seymour JF, Talpaz M, Kurzrock R. Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. Leukemia 1997; 11:42.</a></li><li><a class="nounderline abstract_t">Juliusson G, Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2'-deoxyadenosine (CdA): relation to opportunistic infections. Blood 1992; 79:888.</a></li><li><a class="nounderline abstract_t">Ho AD, Thaler J, Mandelli F, et al. Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1989; 7:1533.</a></li><li><a class="nounderline abstract_t">Johnston JB, Glazer RI, Pugh L, Israels LG. The treatment of hairy-cell leukaemia with 2'-deoxycoformycin. Br J Haematol 1986; 63:525.</a></li><li><a class="nounderline abstract_t">Spiers AS, Moore D, Cassileth PA, et al. Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin). N Engl J Med 1987; 316:825.</a></li><li><a class="nounderline abstract_t">Blick M, Lepe-Zuniga JL, Doig R, Quesada JR. Durable complete remissions after 2'-deoxycoformycin treatment in patients with hairy cell leukemia resistant to interferon alpha. Am J Hematol 1990; 33:205.</a></li><li><a class="nounderline abstract_t">Cassileth PA, Cheuvart B, Spiers AS, et al. Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol 1991; 9:243.</a></li><li><a class="nounderline abstract_t">Catovsky D, Matutes E, Talavera JG, et al. Long term results with 2'deoxycoformycin in hairy cell leukemia. Leuk Lymphoma 1994; 14 Suppl 1:109.</a></li><li><a class="nounderline abstract_t">Dearden C, Catovsky D. Treatment of Hairy Cell Leukaemia with 2'-Deoxycoformycin. Leuk Lymphoma 1990; 1:179.</a></li><li><a class="nounderline abstract_t">Golomb HM, Dodge R, Mick R, et al. Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study 8515. Leukemia 1994; 8:2037.</a></li><li><a class="nounderline abstract_t">Kraut EH, Bouroncle BA, Grever MR. Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 1989; 7:168.</a></li><li><a class="nounderline abstract_t">Kraut EH, Grever MR, Bouroncle BA. Long-term follow-up of patients with hairy cell leukemia after treatment with 2'-deoxycoformycin. Blood 1994; 84:4061.</a></li><li><a class="nounderline abstract_t">Maloisel F, Benboubker L, Gardembas M, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 2003; 17:45.</a></li><li><a class="nounderline abstract_t">Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000; 96:2981.</a></li><li><a class="nounderline abstract_t">Polliack A, Dann EJ. Rapid massive splenic relapse of hairy cell leukemia (HCL) during bone marrow remission after 2-chlorodeoxyadenosine therapy: the spleen as a sanctuary site in HCL? Blood 1994; 84:2057.</a></li><li><a class="nounderline abstract_t">Stiles GM, Stanco LM, Saven A, Hoffmann KD. Splenectomy for hairy cell leukemia in pregnancy. J Perinatol 1998; 18:200.</a></li><li><a class="nounderline abstract_t">Golomb HM, Vardiman JW. Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood 1983; 61:349.</a></li><li><a class="nounderline abstract_t">Jansen J, Hermans J. Splenectomy in hairy cell leukemia: a retrospective multicenter analysis. Cancer 1981; 47:2066.</a></li><li><a class="nounderline abstract_t">Van Norman AS, Nagorney DM, Martin JK, et al. Splenectomy for hairy cell leukemia. A clinical review of 63 patients. Cancer 1986; 57:644.</a></li><li><a class="nounderline abstract_t">Magee MJ, McKenzie S, Filippa DA, et al. Hairy cell leukemia. Durability of response to splenectomy in 26 patients and treatment of relapse with androgens in six patients. Cancer 1985; 56:2557.</a></li><li><a class="nounderline abstract_t">Ellison DJ, Sharpe RW, Robbins BA, et al. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1994; 84:4310.</a></li><li><a class="nounderline abstract_t">Hakimian D, Tallman MS, Kiley C, Peterson L. Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1993; 82:1798.</a></li><li><a class="nounderline abstract_t">Wheaton S, Tallman MS, Hakimian D, Peterson L. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 1996; 87:1556.</a></li><li><a class="nounderline abstract_t">Sigal DS, Sharpe R, Burian C, Saven A. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 2010; 115:1893.</a></li><li><a class="nounderline abstract_t">Filleul B, Delannoy A, Ferrant A, et al. A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 1994; 8:1153.</a></li><li><a class="nounderline abstract_t">Cervetti G, Galimberti S, Andreazzoli F, et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia. Eur J Haematol 2004; 73:412.</a></li><li><a class="nounderline abstract_t">Arons E, Margulies I, Sorbara L, et al. Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction. Clin Cancer Res 2006; 12:2804.</a></li><li><a class="nounderline abstract_t">Grever MR. Hairy cell: young living longer but not cured. Blood 2014; 123:150.</a></li><li><a class="nounderline abstract_t">Else M, Dearden CE, Matutes E, et al. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma 2011; 52 Suppl 2:75.</a></li><li><a class="nounderline abstract_t">Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003; 102:810.</a></li><li><a class="nounderline abstract_t">Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 2001; 115:609.</a></li><li><a class="nounderline abstract_t">Thomas DA, O'Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003; 102:3906.</a></li><li><a class="nounderline abstract_t">Cervetti G, Galimberti S, Andreazzoli F, et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-up. Br J Haematol 2008; 143:296.</a></li><li><a class="nounderline abstract_t">Else M, Osuji N, Forconi F, et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer 2007; 110:2240.</a></li><li><a class="nounderline abstract_t">Gerrie AS, Zypchen LN, Connors JM. Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. Blood 2012; 119:1988.</a></li><li><a class="nounderline abstract_t">Tiacci E, De Carolis L, Simonetti E, et al. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. N Engl J Med 2021; 384:1810.</a></li><li><a class="nounderline abstract_t">Tiacci E, Park JH, De Carolis L, et al. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med 2015; 373:1733.</a></li><li><a class="nounderline abstract_t">Tiacci E, De Carolis L, Simonetti E, et al. Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial. Leukemia 2021; 35:3314.</a></li><li><a class="nounderline abstract_t">Handa S, Lee JO, Derkach A, et al. Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy. Blood 2022; 140:2663.</a></li><li><a class="nounderline abstract_t">Liebers N, Roider T, Bohn JP, et al. BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials. Leukemia 2020; 34:1454.</a></li><li><a class="nounderline abstract_t">Kreitman RJ, Moreau P, Ravandi F, et al. Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia. Blood 2023; 141:996.</a></li><li><a class="nounderline abstract_t">Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med 2023; 29:1103.</a></li><li><a class="nounderline abstract_t">Tiacci E, De Carolis L, Santi A, Falini B. Venetoclax in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med 2023; 388:952.</a></li><li><a class="nounderline abstract_t">Forconi F, Ashton-Key M, Meakin N. BCL2 Inhibition in Refractory Hairy-Cell Leukemia. N Engl J Med 2023; 388:2010.</a></li><li><a class="nounderline abstract_t">Sivina M, Kreitman RJ, Arons E, et al. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br J Haematol 2014; 166:177.</a></li><li><a class="nounderline abstract_t">Bohn JP, Wanner D, Steurer M. Ibrutinib for relapsed refractory hairy cell leukemia variant. Leuk Lymphoma 2017; 58:1224.</a></li><li><a class="nounderline abstract_t">Rogers KA, Andritsos LA, Wei L, et al. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. Blood 2021; 137:3473.</a></li><li class="breakAll">Dear Healthcare Provider letter: Important information for LUXMOXITI. US Food and Drug Administration. Available at: https://www.fda.gov/media/164425/download (Accessed on January 20, 2023).</li><li><a class="nounderline abstract_t">Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001; 345:241.</a></li><li><a class="nounderline abstract_t">Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006; 6:559.</a></li><li><a class="nounderline abstract_t">Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005; 23:6719.</a></li><li><a class="nounderline abstract_t">Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009; 27:2983.</a></li><li><a class="nounderline abstract_t">Salvatore G, Beers R, Margulies I, et al. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res 2002; 8:995.</a></li><li><a class="nounderline abstract_t">Kreitman RJ, Tallman MS, Robak T, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012; 30:1822.</a></li><li><a class="nounderline abstract_t">Kreitman RJ, Tallman MS, Robak T, et al. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood 2018; 131:2331.</a></li><li><a class="nounderline abstract_t">Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia 2018; 32:1768.</a></li><li><a class="nounderline abstract_t">Kampmeier P, Spielberger R, Dickstein J, et al. Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assessment. Blood 1994; 83:2931.</a></li><li><a class="nounderline abstract_t">Kurzrock R, Strom SS, Estey E, et al. Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol 1997; 15:1803.</a></li><li><a class="nounderline abstract_t">Au WY, Klasa RJ, Gallagher R, et al. Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience. Blood 1998; 92:1160.</a></li><li><a class="nounderline abstract_t">Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999; 17:2454.</a></li><li><a class="nounderline abstract_t">Federico M, Zinzani PL, Frassoldati A, et al. Risk of second cancer in patients with hairy cell leukemia: long-term follow-up. J Clin Oncol 2002; 20:638.</a></li><li><a class="nounderline abstract_t">Hisada M, Chen BE, Jaffe ES, Travis LB. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst 2007; 99:215.</a></li><li><a class="nounderline abstract_t">Cornet E, Tomowiak C, Tanguy-Schmidt A, et al. Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia. Br J Haematol 2014; 166:390.</a></li><li><a class="nounderline abstract_t">Getta BM, Woo KM, Devlin S, et al. Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia. Br J Haematol 2016; 175:402.</a></li><li><a class="nounderline abstract_t">Golomb HM, Catovsky D, Golde DW. Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med 1978; 89:677.</a></li><li><a class="nounderline abstract_t">Chandran R, Gardiner SK, Smith SD, Spurgeon SE. Improved survival in hairy cell leukaemia over three decades: a SEER database analysis of prognostic factors. Br J Haematol 2013; 163:407.</a></li><li><a class="nounderline abstract_t">Hounshell J, Tomori C, Newlin R, et al. Changes in finances, insurance, employment, and lifestyle among persons diagnosed with hairy cell leukemia. Oncologist 2001; 6:435.</a></li><li class="breakAll">www.histio.org (Accessed on June 10, 2010).</li></ol></div><div id="topicVersionRevision">Topic 4535 Version 51.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27903528" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21504285" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Infectious complications in hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21122460" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Incidence, risk of infection and survival of hairy cell leukaemia in Denmark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19302557" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Risk factors for severe infection in patients with hairy cell leukemia: a long-term study of 73 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24706230" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Infections in patients with leukemia and lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24277451" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27301277" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34607348" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16781083" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Current treatment options in hairy cell leukemia and hairy cell leukemia variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19745070" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20558005" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33053222" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33053222" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7707126" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25361945" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19344416" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16245328" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19843881" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : How I treat hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10460614" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1969613" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8822913" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9060556" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9731048" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Long-term follow-up of patients with hairy cell leukemia after cladribine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12610190" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9180283" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9738569" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8823495" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A limited sampling strategy for estimation of the cladribine plasma area under the concentration versus time curve after intermittent i.v. infusion, s.c. injection, and oral administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8622049" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8724536" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10091389" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17209059" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7707128" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32777066" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1357107" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10194424" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10512174" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Technetium-99m sulfur colloid scanning and correlative magnetic resonance imaging in patients with hairy cell leukemia and hypocellular bone marrow biopsies after 2-chlorodeoxyadenosine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24192579" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15761021" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7820043" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7910051" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15229616" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21821712" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16497968" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Eradication of minimal residual disease in hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32109194" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2783373" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9001417" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1346578" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2'-deoxyadenosine (CdA): relation to opportunistic infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2789273" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3488071" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The treatment of hairy-cell leukaemia with 2'-deoxycoformycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2434850" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2301379" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Durable complete remissions after 2'-deoxycoformycin treatment in patients with hairy cell leukemia resistant to interferon alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1988572" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pentostatin induces durable remissions in hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7820041" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Long term results with 2'deoxycoformycin in hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27463984" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment of Hairy Cell Leukaemia with 2'-Deoxycoformycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7807991" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study 8515.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2783731" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pentostatin in the treatment of advanced hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7994024" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Long-term follow-up of patients with hairy cell leukemia after treatment with 2'-deoxycoformycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12529659" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11049974" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8081009" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Rapid massive splenic relapse of hairy cell leukemia (HCL) during bone marrow remission after 2-chlorodeoxyadenosine therapy: the spleen as a sanctuary site in HCL?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9659649" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Splenectomy for hairy cell leukemia in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6821700" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7226099" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Splenectomy in hairy cell leukemia: a retrospective multicenter analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3943001" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Splenectomy for hairy cell leukemia. A clinical review of 63 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4052933" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hairy cell leukemia. Durability of response to splenectomy in 26 patients and treatment of relapse with androgens in six patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7994047" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7691237" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8608247" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20056789" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7913513" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15522063" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Rituximab as treatment for minimal residual disease in hairy cell leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16675574" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24408202" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Hairy cell: young living longer but not cured.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21504288" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12663446" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11736943" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12816862" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Rituximab in relapsed or refractory hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18710384" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17886250" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22223825" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Fludarabine and rituximab for relapsed or refractory hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33979489" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26352686" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33731847" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35930750" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31740808" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36108341" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37059834" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36884329" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Venetoclax in Relapsed or Refractory Hairy-Cell Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37224205" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : BCL2 Inhibition in Refractory Hairy-Cell Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24697238" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27733095" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Ibrutinib for relapsed refractory hairy cell leukemia variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33754642" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Phase 2 study of ibrutinib in classic and variant hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33754642" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Phase 2 study of ibrutinib in classic and variant hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11474661" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16794638" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Immunotoxin therapy of cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16061911" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19414673" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11948105" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22355053" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29487070" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30030507" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8180388" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9164188" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Second cancer risk in hairy cell leukemia: analysis of 350 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9694703" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561309" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11821443" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Risk of second cancer in patients with hairy cell leukemia: long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17284716" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24749839" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27351754" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/717940" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Hairy cell leukemia: a clinical review based on 71 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23889044" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Improved survival in hairy cell leukaemia over three decades: a SEER database analysis of prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11675521" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Changes in finances, insurance, employment, and lifestyle among persons diagnosed with hairy cell leukemia.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
